Targeted and untargeted urinary metabolic profiling of bladder cancer

Ossoliński, Krzysztof; Ruman, Tomasz; Copié, Valérie; Tripet, Brian; Kołodziej, Artur; Płaza, Aneta; Ossolińska, Anna; Ossoliński, Tadeusz; Nieczaj, Anna; Nizioł, Joanna

doi:10.1016/j.jpba.2023.115473

Cited by 7 publications

(10 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, NMR can provide a non-specific and non-destructive quality and quantitative characterization of metabolites, with minimal sample preparation required [ 42 , 43 ]. Within the 25 selected experimental studies for this work ( Figure 1 ), only three relied on NMR-based approaches [ 44 , 45 , 46 ], while the majority used MS-based ones, often in combination with separation techniques such as LC and GC. GC-MS was used in 4 out of 25 selected papers, identifying 124 potentially altered volatile metabolites in association with BCa pathophysiology [ 20 , 35 , 36 , 47 ].…”

Section: Resultsmentioning

confidence: 99%

“…Interestingly, from the 38 metabolites found to be altered in the BCa cases of both studies, succinate was a common metabolite; however, it was found to be both increased [ 54 ] and decreased [ 23 ]. A recent study has also demonstrated decreased levels of succinate in urine-derived samples from BCa patients [ 46 ]. Succinate is an intermediate metabolite in the tricarboxylic acid (TCA) cycle that was demonstrated to play a role in inflammation, oxidative stress, ischemia, hypoxia and immune signaling [ 55 , 56 , 57 ].…”

Section: Resultsmentioning

confidence: 99%

“…These include branched-chain amino acids (BCAA), valine and leucine [ 23 , 47 ] as increased metabolites, along with glycine [ 45 , 47 ] and myristic acid [ 17 , 47 ] as decreased metabolites. Notwithstanding, in the case of valine, leucine and glycine, these have recently displayed contradicting results in the study of Ossoliński and coworkers; that is, valine and leucine exhibited decreased urinary levels, whereas glycine revealed increased urinary levels in comparison to healthy controls [ 46 ]. Interestingly, BCAA metabolism has been marked as a potential oncogenic metabolic pathway in the sense that it may be perturbed due to increased biosynthetic and nutritional demands involved in tumor progression [ 109 ].…”

Section: Resultsmentioning

confidence: 99%

“…↑: increase; ↓: decrease. BCa: bladder cancer; HG: high grade; LG: low grade; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer [ 17 , 18 , 19 , 23 , 30 , 33 , 34 , 38 , 39 , 46 , 54 , 60 , 72 , 106 ].…”

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Pereira,

Domingues,

Vitorino

et al. 2024

IJMS

View full text Add to dashboard Cite

Bladder cancer (BCa) research relying on Omics approaches has increased over the last few decades, improving the understanding of BCa pathology and contributing to a better molecular classification of BCa subtypes. To gain further insight into the molecular profile underlying the development of BCa, a systematic literature search was performed in PubMed until November 2023, following the PRISMA guidelines. This search enabled the identification of 25 experimental studies using mass spectrometry or nuclear magnetic resonance-based approaches to characterize the metabolite signature associated with BCa. A total of 1562 metabolites were identified to be altered by BCa in different types of samples. Urine samples displayed a higher likelihood of containing metabolites that are also present in bladder tumor tissue and cell line cultures. The data from these comparisons suggest that increased concentrations of L-isoleucine, L-carnitine, oleamide, palmitamide, arachidonic acid and glycoursodeoxycholic acid and decreased content of deoxycytidine, 5-aminolevulinic acid and pantothenic acid should be considered components of a BCa metabolome signature. Overall, molecular profiling of biological samples by metabolomics is a promising approach to identifying potential biomarkers for early diagnosis of different BCa subtypes. However, future studies are needed to understand its biological significance in the context of BCa and to validate its clinical application.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Pereira,

Domingues,

Vitorino

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Ruman’s group, for urine [ 50 ] and blood serum [ 51 ] metabolite analyses, utilized the developed SALDI targets coated with monoisotopic silver ( 109 Ag) and gold (Au) nanoparticles generated through the laser ablation synthesis in solution process. Statistical analysis of the MS data enabled the complete separation of the study group with diagnosed bladder cancer from healthy volunteers, as well as the selection of m / z values that most differentiated both groups for further analysis.…”

Section: Bladder Cancermentioning

confidence: 99%

Matrix- and Surface-Assisted Laser Desorption/Ionization Mass Spectrometry Methods for Urological Cancer Biomarker Discovery—Metabolomics and Lipidomics Approaches

Arendowski

2024

Metabolites

View full text Add to dashboard Cite

Urinary tract cancers, including those of the bladder, the kidneys, and the prostate, represent over 12% of all cancers, with significant global incidence and mortality rates. The continuous challenge that these cancers present necessitates the development of innovative diagnostic and prognostic methods, such as identifying specific biomarkers indicative of cancer. Biomarkers, which can be genes, proteins, metabolites, or lipids, are vital for various clinical purposes including early detection and prognosis. Mass spectrometry (MS), particularly soft ionization techniques such as electrospray ionization (ESI) and laser desorption/ionization (LDI), has emerged as a key tool in metabolic profiling for biomarker discovery, due to its high resolution, sensitivity, and ability to analyze complex biological samples. Among the LDI techniques, matrix-assisted laser desorption/ionization (MALDI) and surface-assisted laser desorption/ionization (SALDI) should be mentioned. While MALDI methodology, which uses organic compounds as matrices, is effective for larger molecules, SALDI, based on the various types of nanoparticles and nanostructures, is preferred for smaller metabolites and lipids due to its reduced spectral interference. This study highlights the application of LDI techniques, along with mass spectrometry imaging (MSI), in identifying potential metabolic and lipid biomarkers for urological cancers, focusing on the most common bladder, kidney, and prostate cancers.

show abstract